Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
ISSN-L : 1346-9843
Arrhythmia/Electrophysiology
Clinical Significance of Collateral Superficial Vein Across Clavicle in Patients With Cardiovascular Implantable Electronic Device
Junya HosodaToshiyuki IshikawaKohei MatsushitaKatsumi MatsumotoTeruyasu SuganoTomoaki IshigamiKazuo KimuraSatoshi Umemura
Author information
JOURNAL FREE ACCESS FULL-TEXT HTML

2014 Volume 78 Issue 8 Pages 1846-1850

Details
Abstract

Background: Obstruction of the access vein is a well-known complication after cardiovascular implantable electronic device (CIED) implantation. In that case, well-developed collateral superficial veins are frequently observed on the skin surface around the CIED. The aim of this study was to clarify the relationship between venous obstruction and development of a superficial vein across the clavicle.

Methods and Results: A total of 107 patients scheduled for generator replacement, device upgrade, or lead extraction were enrolled. The skin surface around the device was photographed. A 20-ml bolus of contrast medium was injected into a peripheral arm vein on the side of CIED implantation, and contrast venography was performed. Venous obstruction was defined as luminal diameter narrowing >75%. Venography showed venous obstruction in 27 patients (25.2%). There were no statistically significant differences in patient characteristics between the venous obstruction and no venous obstruction group. Of 107 patients, 44 (41.1%) had a superficial vein across the clavicle on the side of CIED implantation. The sensitivity of the presence of a superficial vein across the clavicle in the diagnosis of venous obstruction was 96.3% and specificity was 77.5% (P<0.001).

Conclusions: The presence of a superficial vein across the clavicle is useful for the prediction of venous obstruction in patients with CIED. (Circ J 2014; 78: 1846–1850)

The number of cardiovascular implantable electronic devices (CIED) in use continues to grow worldwide because of their potency for the treatment of ventricular tachyarrhythmia and heart failure. There is controversy, however, regarding the implantation of permanent electrodes in relation to induction of obstruction of the access vein. Several investigators have shown that during the following period after implantation of pacing leads, venous obstruction was observed in 10–35% of CIED patients.18 Venous obstruction and thrombosis may impede lead extraction,5 increase the risk of pulmonary embolizm,911 induce superior vena cava syndrome,12,13 or affect hemodialysis access patency.14 At present, venography is considered the gold standard for the diagnosis of venous obstruction,15 but venography requires use of an iodinated contrast agent, which may cause allergic reaction or nephrotoxicity. Recently, venous Doppler ultrasonography has been utilized in some prospective studies, but has limitations in diagnosing innominate vein obstruction.2,6,16

Well-developed superficial veins are frequently observed on the skin surface around the CIED during follow-up. In the case of venous obstruction in CIED-implanted patients, contrast venography shows that the main routes of collateral circulation frequently run toward the jugular vein.1,3 Therefore, we considered that collateral circulation close to the skin surface may run across the clavicle and reach the jugular vein. To the best of our knowledge, research on the collateral superficial vein around the CIED correlating with venous obstruction has not yet been reported. Therefore, we investigated the collateral superficial vein across the clavicle as a non-invasive predictor of venous obstruction. The aim of the present study was to clarify the relationship between obstruction of the access vein and development of a superficial vein across the clavicle after CIED implantation.

Methods

A total of 107 patients scheduled for generator replacement, device upgrade, or lead extraction at Yokohama City University Hospital between 2010 and 2013 were enrolled. Patients with renal insufficiency (serum creatinine ≥2.0 mg/dl) or a history of contrast medium hypersensitivity were excluded. The skin surface around the implanted device was photographed with a digital camera in all patients, and the development of superficial veins visible on the skin surface was carefully observed. This study was approved by the Yokohama City University Hospital Ethics Committee (approval number B080703013), and written informed consent was obtained from all patients.

Contrast venography was performed by placing a cannula in a peripheral arm vein on the side of CIED implantation, and a 20-ml bolus of contrast medium was injected through the cannula before generator replacement, device upgrade, or lead extraction. Contrast medium flow in the axillary vein, subclavian vein, innominate vein, and superior vena cava as well as collateral circulation was observed and recorded on cineangiography. Freeze-frame images with complete opacification of the lumen by contrast medium were selected for measurement. The narrowest and widest points of the target vessels were identified by visual inspection to obtain minimum and maximum venous diameters.

Statistical Analysis

Comparisons of quantitative and categorical variables between groups were done using Pearson chi-squared test or Student’s t-test. All continuous data are expressed as mean ± SD. For all tests, P<0.05 was considered statistically significant. All statistical analysis was carried out using SPSS.

Results

Baseline Characteristics

The mean subject age was 68.9±14.4 years, and 62% were men. The indication for original device implantation was sick sinus syndrome in 42%, atrioventricular block in 28%, ventricular tachycardia in 21%, and refractory heart failure in 7%. There were 76 patients with a pacemaker, 25 with an implantable cardioverter defibrillator (ICD), and 6 with a cardiac resynchronization therapy-defibrillator (CRT-D) or cardiac resynchronization therapy-pacemaker (CRT-P). The mean number of leads was 2.0±0.5. The underlying disease was hypertension in 41%, diabetes mellitus in 12%, atrial fibrillation in 31%, cerebral infarction in 7%, dilated cardiomyopathy in 10%, and coronary artery disease in 4%. The proportion of patients receiving warfarin was 27%, and that receiving antiplatelet drugs was 20%. Mean baseline serum creatinine was 1.05±1.14 mg/dl, and d-dimer was 1.18±2.69 mg/dl. Echocardiographic evaluation was performed before generator replacement, lead revision, or device upgrade. Mean left ventricular ejection fraction (LVEF) was 61.9±14.0%.

Contrast Venography

Mean follow-up period after initial implantation was 119.9±70.8 months. Contrast medium-associated complications were not seen in any patients during the acute period or at follow-up. Venous obstruction was defined as luminal diameter narrowing >75%. Contrast venography showed venous obstruction in 27 (25.2%) of 107 patients. Each patient had well-developed venous collateral circulation. Of 27 patients with venous obstruction, 18 had total occlusion. The site of venous obstruction was the left subclavian vein in 17 of 27 patients, right subclavian vein in 1 patient, and left innominate vein in 9 patients.

Risk Factors for Venous Obstruction

The patients were divided into 2 groups: a venous obstruction group (n=27) and a no venous obstruction group (n=80). Clinical characteristics were compared between the 2 groups, and risk factors for venous obstruction were investigated (Table). There were no statistically significant differences in age, sex, diabetes mellitus, atrial fibrillation, or follow-up period after initial implantation between the 2 groups. There were also no statistically significant differences in number of leads, LVEF, or use of warfarin or antiplatelet drugs.

Table. Baseline Patient Characteristics
  Venous obstruction (n=27) No venous obstruction (n=80) P-value
Age (years) 69.4±13.5 68.8±14.8 0.857
Male 15 (55.6) 51 (63.8) 0.454
Pacemaker 17 (63.0) 59 (73.8) 0.290
ICD 8 (29.6) 17 (21.3) 0.378
CRT-D(P) 2 (7.4) 4 (5.0) 0.642
Period after implantation (months) 102.6±72.7 125.9±69.5 0.140
No. leads 2.07±0.39 1.98±0.55 0.389
Hypertension 11 (40.7) 33 (41.2) 0.963
Diabetes mellitus 2 (7.4) 11 (13.8) 0.388
Smoke 11 (40.7) 33 (41.3) 0.963
Atrial fibrillation 9 (33.3) 24 (30.0) 0.749
EF (%) 58.7±18.0 63.0±12.4 0.227
Creatinine (mg/dl) 1.17±1.65 1.01±0.91 0.534
d-Dimer >1 μg/ml 10 (37.0) 21 (26.3) 0.246
Warfarin 10 (37.0) 19 (23.8) 0.183
Antiplatelet drugs 6 (22.2) 15 (18.8) 0.698
ACEI or ARB 13 (48.1) 26 (32.5) 0.147
β-blocker 8 (29.6) 13 (16.3) 0.133

Data given as mean ± SD or n (%).

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRT-D(P), cardiac resynchronization therapy-defibrillator/pacemaker; EF, ejection fraction; ICD, implantable cardioverter defibrillator.

Significance of Collateral Superficial Vein Across Clavicle

We focused on the presence of a collateral superficial vein across the clavicle visible on the skin surface. Of 107 patients, 44 (41.1%) had a superficial vein across the clavicle on the side of CIED implantation. Among these patients, we describe the case of a typical patient who had a superficial vein across the clavicle together with vein obstruction, as follows. Patient 1 was a 67-year-old man, in whom a pacemaker had been implanted 6 years previously, and who was referred for pacemaker replacement because of battery depletion. Collateral superficial veins across the left clavicle were clearly observed on the skin surface (Figure 1). Contrast venography just before pacemaker replacement showed total occlusion of the left innominate vein with collateral circulation toward the jugular vein (Figure 2). Patient 2 (a 59-year-old woman in whom an ICD was implanted 6 months previously) is shown in Figures 3, 4. This patient was referred for left ventricular pacing lead implantation and device upgrade to CRT-D. Superficial veins across the clavicle were seen on the skin surface (Figure 3). Contrast venography showed total occlusion of the left subclavian vein with collateral circulation toward the jugular vein (Figure 4).

Figure 1.

Collateral superficial veins across the left clavicle clearly observed on the skin surface in a 67-year-old man (patient 1) in whom a pacemaker was implanted 6 years previously. (A) Photograph; (B) illustration.

Figure 2.

Contrast venography just before pacemaker replacement in patient 1, showing total occlusion of the left innominate vein with collateral circulation toward the jugular vein.

Figure 3.

Superficial veins across the clavicle seen on the skin surface in patient 2, a 59-year-old woman in whom an implantable cardioverter defibrillator was implanted 6 months previously. (A) Photograph; (B) illustration.

Figure 4.

Contrast venography in patient 2, showing total occlusion of the left subclavian vein with collateral circulation toward the jugular vein.

A total of 107 patients were subdivided into 4 groups: venous obstruction with superficial vein across clavicle (subgroup A); venous obstruction without superficial vein across clavicle (subgroup B); no venous obstruction with superficial vein across clavicle (subgroup C); and no venous obstruction without superficial vein across clavicle (subgroup D); and the numbers in subgroups A, B, C, and D were 26, 1, 18, and 62, respectively. Accordingly, the sensitivity of the presence of a superficial vein across the clavicle in the diagnosis of venous obstruction was 96.3% and specificity was 77.5% (P<0.001).

Discussion

The present study suggests that the presence of a superficial vein across the clavicle is useful for the prediction of venous obstruction in patients with CIED.

There are several reports about venous obstruction after CIED implantation. The first large study reported by Goto et al evaluated 100 consecutive patients undergoing elective replacement of a pacemaker.1 Twenty-one venograms (21%) showed moderate-severe venous stenosis, defined as luminal diameter narrowing >50% in 9 patients and total occlusion in 12 patients. Oginosawa et al noted venous obstruction >60% in 26 (32.9%) of 79 patients after implantation of pacing leads.3 Da Costa et al evaluated a large sample of 202 patients 6 months after pacemaker implantation and reported that venography showed severe stenosis (70–99% narrowing) in 31 patients (15%) and total occlusion in 12 patients (6%).4 Recently, widening of the indications and technological advances have resulted in a marked increase in ICD and CRT-D (-P) implantation.17,18 Follow-up procedures such as generator replacement and lead extraction are also expected to rapidly increase. Lickfett et al reported that contrast venography performed prior to the first elective ICD generator replacement showed complete occlusion in 9% and severe stenosis (>75%) in 6% of 105 patients.19 In the present study, a total of 107 patients scheduled for pacemaker or ICD or CRT-D (-P) generator replacement, device upgrade, or lead extraction were enrolled. Contrast venography showed venous obstruction, which was defined as luminal diameter narrowing >75%, in 27 (25.2%) of 107 patients. Of the 27 patients with the venous obstruction, 18 had total occlusion. The occurrence rate of venous obstruction in the present study was similar to that in previous studies. Although the pathogenesis of venous thrombosis and obstruction has not yet been determined, possible causes are considered to be endothelial trauma caused by lead insertion, central extension of thrombosis from a ligated access vein, and a postoperative hypercoagulable state.

Van Rooden et al evaluated 145 patients on serial venous Doppler ultrasonography before and after pacemaker or ICD implantation, and found that absence of anticoagulant therapy, use of female hormone therapy, and a history of venous thrombosis were associated with an increased risk of venous thrombosis.6 Haghjoo et al suggested that the number of implanted leads (P=0.039; odds ratio [OR], 2.22) and anticoagulant or antiplatelet therapy (P=0.044; OR, 2.79) were independent predictors of venous obstruction after CIED implantation.20 Most previous studies, however, have found no difference in the incidence of venous obstruction related to patient characteristics, such as age, sex, number of implanted leads, time from initial implantation, LVEF, or use of anticoagulant or antiplatelet drugs.13,21 A recent prospective venography-based study of 150 consecutive pacemaker implantations showed that no single clinical factor predicted venous thrombosis.22 Postoperative levels of plasma markers of coagulation and endothelial activation (prothrombin fragment 1+2, d-dimer, von Willebrand factor, thrombomodulin) also did not predict venous thrombosis. We also could not identify risk factors for the incidence of venous obstruction after implantation of pacing leads. Therefore, further study with a larger sample size is needed to establish the risk factors for venous obstruction.

Well-developed superficial veins were frequently observed on the skin surface around the CIED during follow-up. In cases of obstruction of the access vein after CIED implantation, contrast venography showed that the main routes of collateral circulation frequently ran toward the internal or external jugular vein.1,3 Therefore, we considered that newly developed collateral circulation close to the skin surface may run across the clavicle and reach the jugular vein, and conducted a study to test the hypothesis that a collateral superficial vein across a clavicle visible on the skin surface might be a valuable predictor of venous obstruction. In 107 patients, 44 (41.1%) had a superficial vein across the clavicle on the side of CIED implantation. As already noted, 27 patients developed venous obstruction, of whom 26 were found to have a superficial vein across the clavicle. In contrast, of 80 patients with no venous obstruction, 62 did not have a superficial vein across the clavicle. Accordingly, the sensitivity of the presence of a superficial vein across the clavicle in the diagnosis of venous obstruction was calculated to be 96.3% and specificity was 77.5% (P<0.001). These results, especially the high sensitivity, suggest that the presence of a superficial vein across the clavicle can be useful for the prediction of venous obstruction in patients with CIED. The specificity, however, was not relatively high because 18 patients with no venous obstruction had a superficial vein across the clavicle. In order to clarify the cause of this specificity, we examined these 18 patients and found that most of them had some collateral circulation toward the jugular vein in spite of having no venous obstruction. Considering that collateral circulation toward the jugular vein generally reflects the existence of some disorder of blood flow, these patients might have had some risk of development of venous obstruction caused by blood flow disturbance due to the pacing lead itself in the future, which needs further investigation.

Another non-invasive method of detecting venous obstruction is ultrasonography. According to Nishino et al, ultrasonography can accurately show severe access vein stenosis due to thrombosis after CIED implantation.16 It was difficult, however, to visually detect the proximal or distal innominate vein and superior vena cava precisely on ultrasonography. We first focused on the superficial veins on the skin surface around the CIED, and found a collateral superficial vein across the clavicle to be a simple and non-invasive marker to predict venous obstruction without difficulty compared with ultrasonography. This suggests that most patients without a superficial vein across a clavicle do not have obstruction of the access vein, and contrast venography might be unnecessary. In contrast, in patients with a superficial vein across a clavicle, the present findings underline the importance of contrast venography, especially when adding or extracting a CIED lead.

In order to confirm this result, however, we have to consider the following study limitations. One possible limitation is that this study was a small-sample-size, single-center analysis. Venous obstruction in some patients with de novo CIED implantation is a significant issue. In the present study, however, contrast venography was not performed and the development of superficial veins visible on the skin surface was not assessed before CIED implantation, which are other limitations. Further study with a larger sample size is needed to confirm the present results.

Conclusions

The presence of a collateral superficial vein on the skin surface around the CIED during follow-up is very closely correlated with obstruction of the access vein. Especially, the presence of a superficial vein across the clavicle is useful for the prediction of venous obstruction in patients with CIED.

References
  • 1.    Goto Y, Abe T, Sekine S, Sakurada T. Long-term thrombosis after transvenous permanent pacemaker implantation. Pacing Clin Electrophysiol 1998; 21: 1192–1195.
  • 2.    Zuber M, Huber P, Fricker U, Buser P, Jager K. Assessment of the subclavian vein in patients with transvenous pacemaker leads. Pacing Clin Electrophysiol 1998; 21: 2621–2630.
  • 3.    Oginosawa Y, Abe H, Nakashima Y. The incidence and risk factors for venous obstruction after implantation of transvenous pacing leads. Pacing Clin Electrophysiol 2002; 25: 1605–1611.
  • 4.    Da Costa SS, Scalabrini NA, Costa R, Caldas JG, Martinelli FM. Incidence and risk factors of upper extremity deep vein lesions after permanent transvenous pacemaker implant. Pacing Clin Electrophysiol 2002; 25: 1301–1306.
  • 5.    Bracke F, Meijer A, Van Gelder B. Venous occlusion of the access vein in patients referred for lead extraction: Influence of patient and lead characteristics. Pacing Clin Electrophysiol 2003; 26: 1649–1652.
  • 6.    van Rooden CJ, Molhoek SG, Rosendaal FR, Schalij MJ, Meinders AE, Huisman MV. Incidence and risk factors of early venous thrombosis associated with permanent pacemaker leads. J Cardiovasc Electrophysiol 2004; 15: 1258–1262.
  • 7.    Sticherling C, Chough SP, Baker RL, Wasmer K, Oral H, Tada H, et al. Prevalence of central venous occlusion in patients with chronic defibrillator leads. Am Heart J 2001; 141: 813–816.
  • 8.    Bulur S, Vural A, Yazici M, Ertas G, Ozhan H, Ural D. Incidence and predictors of subclavian vein obstruction following biventricular device implantation. J Interv Card Electrophysiol 2010; 29: 199–202.
  • 9.    Seeger W, Scherer K. Asymptomatic pulmonary embolism following pacemaker implantation. Pacing Clin Electrophysiol 1986; 9: 196–199.
  • 10.    Prozan GB, Shipley RE, Madding GF, Kennedy PA. Pulmonary thromboembolism in the presence of an endocardiac pacing catheter. JAMA 1968; 206: 1564–1565.
  • 11.    Pasquariello JL, Hariman RJ, Yudelman IM, Feit A, Gomes JA, Elsherif N. Recurrent pulmonary embolization following implantation of transvenous pacemaker. Pacing Clin Electrophysiol 1984; 7: 790–793.
  • 12.    Park HW, Kim W, Cho JG, Kang JC. Multiple pacing lead-induced superior vena cava syndrome. J Cardiovasc Electrophysiol 2005; 16: 221–223.
  • 13.    Bolad I, Karanam S, Mathew D, John R, Piemonte T, Martin D. Percutaneous treatment of superior vena cava obstruction following transvenous device implantation. Catheter Cardiovasc Interv 2005; 65: 54–59.
  • 14.    Teruya TH, Abou-Zamzam AM, Limm W, Wong L.  Wong L. Symptomatic subclavian vein stenosis and occlusion in hemodialysis patients with transvenous pacemakers. Ann Vasc Surg 2003; 17: 526–529.
  • 15.    Rozmus G, Daubert JP, Huang DT, Rosero S, Hall B, Francis C. Venous thrombosis and stenosis after implantation of pacemakers and defibrillators (Review). J Interv Card Electrophysiol 2005; 13: 9–19.
  • 16.    Nishino M, Tanouchi J, Ito T, Tanaka K, Aoyama T, Kitamura M, et al. Echographic detection of latent severe thrombotic stenosis of the superior vena cava and innominate vein in patients with a pacemaker: Integrated diagnosis using sonography, pulse Doppler, and color flow. Pacing Clin Electrophysiol 1997; 20: 946–952.
  • 17.    Fang F, Sanderson JE, Yu CM. Potential role of biventricular pacing beyond advanced systolic heart failure. Circ J 2013; 77: 1364–1369.
  • 18.    Momomura S, Tsutsui H, Sugawara Y, Ito M, Mitsuhashi T, Fukamizu S, et al. Clinical efficacy of cardiac resynchronization therapy with an implantable defibrillator in a Japanese population. Circ J 2012; 76: 1911–1919.
  • 19.    Lickfett L, Bitzen A, Arepally A, Nasir K, Wolpert C, Jeong KM, et al. Incidence of venous obstruction following insertion of an implantable cardioverter defibrillator: A study of systematic contrast venography on patients presenting for their first elective ICD generator replacement. Europace 2004; 6: 25–31.
  • 20.    Haghjoo M, Nikoo M, Fazelifar A, Alizadeh A, Emkanjoo Z, Sadr-Ameli MA. Predictors of venous obstruction following pacemaker or implantable cardioverter-defibrillator implantation: A contrast venographic study on 100 patients admitted for generator change, lead revision or device upgrade. Europace 2007; 9: 328–332.
  • 21.    Bar-Cohen Y, Berul CI, Alexander ME, Fortescue EB, Walsh EP, Triedman JK, et al. Age, size, and lead factors alone do not predict venous obstruction in children and young adults with transvenous lead systems. J Cardiovasc Electrophysiol 2006; 17: 754–759.
  • 22.    Korkeila P, Mustonen P, Koistinen J, Nyman K, Ylitalo A, Karjalainen P, et al. Clinical and laboratory risk factors of thrombotic complications after pacemaker implantation: A prospective study. Europace 2010; 12: 817–824.
 
© 2014 2013 THE JAPANESE CIRCULATION SOCIETY
feedback
Top